Toward solving the etiological mystery of primary biliary cholangitis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis (PBC) is considered a model autoimmune disease due to its signature anti‐mitochondrial antibody (AMA) autoantibody, female predominance, and relatively specific portal infiltration and cholestasis. The identification and cloning of the major mitochondrial autoantigens recognized by AMA have served as an immunologic platform to identify the earliest events involved in loss of tolerance. Despite the relatively high concordance rate in identical twins, genome‐wide association studies have not proven clinically useful and have led to suggestions of epigenetic events. To understand the natural history and etiology of PBC, several murine models have been developed, including spontaneous models, models induced by chemical xenobiotic immunization, and by “designer” mice with altered interferon metabolism. Herein, we describe five such models, including 1) NOD.c3c4 mice, 2) dominant negative form of transforming growth factor receptor type II mice, 3) interleukin‐2R α−/−mice, 4) adenylate‐uridylate‐rich element Del−/−mice, and 5) 2‐octynoic acid‐conjugated bovine serum albumin immunized mice. Individually there is no perfect murine model, but collectively the models point to loss of tolerance to PDC‐E2, the major mitochondrial autoantigen, as the earliest event that occurs before clinical disease is manifest. Although there is no direct association of AMA titer and PBC disease progression, it is noteworthy that the triad of PBC monocytes, biliary apotopes, and AMA leads to an intense proinflammatory cytokine burst. Further, the recurrence of PBC after liver transplantation indicates that, due to major histocompatibility complex restriction, disease activity must include not only adaptive immunity but also innate immune mechanisms. We postulate that successful treatment of PBC may require a personalized approach with therapies designed for different stages of disease. (Hepatology Communications 2017;1:275–287)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity
Markle, J. G. M., Frank, D. N., Mortin-Toth, S., Robertson, C. E., Feazel, L. M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K. D., Macpherson, A. J., & Danska, J. S. (2013) · Science · doi:10.1126/science.1233521 · Cited by 2,025
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 2×
“(18-20) Recently, obeticholic acid, a selective ligand of the farnesoid X receptor, was approved for patients who are refractory to UDCA.”
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Gershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497 · cited 1×
“While the introduction of ursodeoxycholic acid (UDCA) for the treatment of PBC greatly improved the outcome,((17)) nearly 30% of patients treated with UDCA show an incomplete response and disease progression.”
Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480
Self-citationGenome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464
Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434 · cited 1×
“pathologic process, genetics, etiology, and natural history of PBC has significantly increased.((4,7,8,15,16,65,79,91,96-100)) The vast amount of information gained from these studies points to the thesis that the loss of tolerance to the PDC-E2 lipoyl domain is a linchpin in the development of the biliary pathology o…”
Self-citationNatural history of early primary biliary cirrhosis
Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421 · cited 1×
“Furthermore, while AMA is typically not found in other liver diseases or autoimmune diseases, a positive AMA in otherwise healthy individuals indicates a substantial risk of future PBC development.((37-39)) These findings suggest that AMAs are not simply serologic markers for diagnosis but are important in the immunop…”
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
Liu, X., Invernizzi, P., Lu, Y., Kosoy, R., Lu, Y., Bianchi, I., Podda, M., Xu, C., Xie, G., Macciardi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.627 · Cited by 398
Self-citationCordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9019 · Cited by 287
Self-citationNakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.08.010 · Cited by 267
Self-citationIL-2 receptor α−/− mice and the development of primary biliary cirrhosis
Wakabayashi, K., Lian, Z.-X., Moritoki, Y., Lan, R. Y., Tsuneyama, K., Chuang, Y.-H., Yang, G.-X., Ridgway, W., Ueno, Y., Ansari, A. A., et al. (2006) · Hepatology · doi:10.1002/hep.21385 · Cited by 233
Kita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Self-citationIncreased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222 · cited 1×
“Other studies suggested significant clustering of patients with PBC, particularly surrounding toxic sites.((66,67)) These epidemiological data, along with the crucial role of AMA in the immunopathology of PBC, prompted us to search for environmental mimotopes in the form of xenobiotics.”
Apotopes and the biliary specificity of primary biliary cirrhosis†
Lleo, A., Selmi, C., Invernizzi, P., Podda, M., Coppel, R. L., Mackay, I. R., Gores, G. J., Ansari, A. A., Van de Water, J., & Gershwin, M. E. (2009) · Hepatology · doi:10.1002/hep.22736 · Cited by 222 · cited 1×
“This supports data in which AMA-containing sera reacted with PDC-E2 on apoptotic BECs without permeabilization.((47)) We then examined the ability of BECs to induce cytokine secretion from mature monocyte-derived macrophages, with and without AMAs and observed intense inflammatory cytokine production in the presence o…”
Self-citationVariants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis
Hirschfield, G. M., Liu, X., Han, Y., Gorlov, I. P., Lu, Y., Xu, C., Lu, Y., Chen, W., Juran, B. D., Coltescu, C., et al. (2010) · Nature Genetics · doi:10.1038/ng.631 · Cited by 215
Yang, C.-Y., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N. P., Bowlus, C. L., Yang, G.-X., Leung, P. S. C., Ansari, A. A., et al. (2014) · Hepatology · doi:10.1002/hep.26979 · Cited by 213 · cited 2×
“Through various assays, we found that IFN-c is crucial to the pathogenesis of autoimmune cholangitis in this model.((89,91)) We should note that activation of na€ıve CD4 T cells from healthy women produces higher levels of IFN-c and lower levels of IL-17 than in healthy men.”
Self-citationFamilial primary biliary cirrhosis reassessed: a geographically-based population study
Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213
Amano, K., Leung, P. S. C., Rieger, R., Quan, C., Wang, X., Marik, J., Suen, Y. F., Kurth, M. J., Nantz, M. H., Ansari, A. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5874 · Cited by 187
Self-citationCharacterization of antimitochondrial antibodies in healthy adults
Mattalia, A., Quaranta, S., Leung, P. S. C., Bauducci, M., Van de Water, J., Calvo, P. L., Danielle, F., Rizzetto, M., Ansari, A., Coppel, R. L., et al. (1998) · Hepatology · doi:10.1002/hep.510270303 · Cited by 146
Self-citationMoteki, S., Leung, P. S., Dickson, E. R., Van Thiel, D. H., Galperin, C., Buch, T., Alarcon-Segovia, D., Kershenobich, D., Kawano, K., Coppel, R. L., et al. (1996) · Hepatology · doi:10.1002/hep.510230307 · Cited by 133 · cited 1×
“The dominant epitope sites recognized by AMA are in contiguity with the LA attachment site(s) as the lipoyl domains of these target antigens.((33-35)) The amino acid residues critical to maintaining the structural integrity of PDC-E2 lipoyl domain have been revealed by sitedirected mutagenesis.”
Self-citationShimoda, S., Harada, K., Niiro, H., Shirabe, K., Taketomi, A., Maehara, Y., Tsuneyama, K., Nakanuma, Y., Leung, P., Ansari, A. A., et al. (2011) · Hepatology · doi:10.1002/hep.24194 · Cited by 126 · cited 1×
“Immunohistochemical examination of these lymphocytes reveals a predominance of CD41 and CD81 T cells with B and natural killer cells.((40,41)) BECs and hepatocytes in the liver of patients with PBC also express large amounts of human leukocyte antigen (HLA) class I and II molecules.”
Self-citationYang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., Chen, X., Bian, Z., Zhang, H., Yang, Y., et al. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8516-5 · Cited by 71
Self-citationHisamoto, S., Shimoda, S., Harada, K., Iwasaka, S., Onohara, S., Chong, Y., Nakamura, M., Bekki, Y., Yoshizumi, T., Ikegami, T., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.08.006 · Cited by 57
Self-citation
Cited by
Molecular mimicry and autoimmunity
Rojas, M., Restrepo-Jiménez, P., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Leung, P. S. C., Ansari, A. A., Gershwin, M. E., & Anaya, J.-M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.012 · Cited by 627
Self-citationThe challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationTerziroli Beretta-Piccoli, B., Mieli-Vergani, G., & Vergani, D. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.004 · Cited by 61
Metadata
- Authors
- Tanaka, A., Leung, P. S. C., Young, H. A., & Gershwin, M. E.
- Venue
- Hepatology Communications
- Published
- 2017-05-18
- Volume
- 1
- Issue
- 4
- Pages
- 275-287
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2616117570
- Cited by
- 37
- References
- 27
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.